Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease (ILD): impact of pulmonary arterial hypertension (PAH) therapies.


  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 13 February 2012 - 01:44 AM

Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease (ILD): impact of pulmonary arterial hypertension (PAH) therapies.

In this cohort, PAH therapies were associated with no clear benefits. Prospective clinical trials focusing on this group of patients are warranted. Arthritis rheumatologist. 2011 Aug;63(8):2456-64.

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)